Drug Delivery Partnerships 2014

Monday, January 27 – Tuesday, January 28, 2014


Catalent Institute Leader, Dr. Cornell Stamoran and other leading experts led a two-day panel discussion at DDP 2014 titled “Improved Patient Outcomes through Better Drug Design: Our Call to Action” and “Designing for Better Outcomes: Turning Concept into Practice.”


Cornell Stamoran led the following session:


Panel Overview: “Improved Patient Outcomes through Better Drug Design: Our Call to Action.”

  • The unmet (or partially met) need for improved outcomes, and very clearly makes the case for more intelligent drug design
  • Aspects of design that are relevant to delivery technologies
  • Products that can deliver better outcomes for patients, and how that in turn affects the marketing company’s likely market access/reimbursement probability
Norm Stroud presented and led the followings sessions in Track 3, “Innovation Theater”:


Soft Capsules: A Versatile Drug Delivery System

The presentation will cover soft capsule formulation technologies with a special emphasis on recent advances that have resulted from the development of polysaccharide-based capsule shells (OptiShell™). The use of the OptiShell™ system for the encapsulation of semi-solid formulations, as well as the more traditional liquid, solution or suspension, capsule fill formulations will be described. The use of the OptiShell™ system as a means to develop optimal IR, CR, and abuse-deterrent formulations will be discussed.

Key Audience Takeaways:

  • An appreciation for the state-of-the-art of soft capsule technologies (rotary-die, and seamless encapsulation)
  • An appreciation of the processing techniques used in recent developments in capsule shell technology
  • An awareness of the versatility of the new, OptiShell™ capsule technology
  • An awareness of advances in the development of IR, CR, and AD capsule fill formulations for general and specialized drug delivery.


Panel Overview: “Designing for Better Outcomes: Turning Concept into Practice.”

  • To build on the call to action earlier, but to discuss very specifically how things in a development process or target product profile setting may need to change



Cornell Stamoran

Vice President, Corporate Development & Strategy

Dr. Stamoran has spent nearly 25 years engaged with the healthcare industry, and has experienced the realities of patient adherence and outcomes enhancement from almost every stakeholder perspective: from direct engagement with retail and hospital pharmacists; medical professionals; specialty pharmacies and clinics; and pharmacy benefit managers and payers. He has directly participated in adherence and outcomes enhancement strategies for more than 150 drugs over the last 10 years.


Norman Stroud

Director, Technology Development

After receiving his B.Sc degree in Biochemistry from Cardiff University, Wales, Mr. Stroud spent 9 years working at the Pharmaceutics Department, School of Pharmacy and Pharmacology, University of Bath, England.  During his time in Academia, he held various positions in Pharmaceutical R&D, with a focus on the development of liquid dosage forms.  In 1982 Norman joined the R&D group of R.P. Scherer UK and held various scientific and managerial positions while working in the field of softgel encapsulation.  After transferring to the St. Petersburg, Florida facility in 1991, he continued to work on formulation and process development of softgels, with a focus on product innovation.  He has been granted 9 US patents.  During his time at Catalent Pharma Solutions (formerly R.P. Scherer/Cardinal Health) Norman has held a variety of functional and leadership roles.  His more recent research studies have focused on the use of polysaccharide-based capsule shells for the encapsulation of pharmaceutical fill formulations. He is currently Director of Technology Development at the Catalent Pharma Solutions facility in St. Petersburg.